<DOC>
	<DOCNO>NCT00827580</DOCNO>
	<brief_summary>A pilot study eniluracil contain ointment prevention hand foot syndrome ( HRS ) follow capecitabine ( Xeloda ) .</brief_summary>
	<brief_title>Eniluracil Hand Foot Syndrome</brief_title>
	<detailed_description>Primary Objectives 1 . To estimate frequency HFS follow treatment capecitabine modulate unilateral local application eniluracil contain ointment . 2 . To assess eniluracil dose response relationship prevention HFS . 3 . To evaluate potential toxicity eniluracil ointment .</detailed_description>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Hand-Foot Syndrome</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Eniluracil</mesh_term>
	<criteria>A subject eligible inclusion study ONLY ALL follow criterion apply : 1 . Signed write informed consent . 2 . Male female , least 18 year age . 3 . Histologically cytologically confirm diagnosis breast colon cancer . 4 . Radiologically document measurable disease 5 . Planned receive capecitabine 10001250 mg/m2 PO twice daily experience grade 1 great HFS previous cycle capecitabine . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 study entry . 7 . Adequate liver function SGOT SGPT &lt; 2.5 time upper limit normal . 8 . Adequate bone marrow function evidence WBC &gt; 2500/mm3 , PMN &gt; 2000/mm3 platelet count &gt; 100,000/mm3 . 9 . Adequate renal function serum creatinine &lt; 1.7 mg/dl . 10 . Recovery relevant toxicity study entry . 11 . Negative serum urine pregnancy test within 7 day study entry woman childbearing potential . Effective contraception throughout course study male female subject risk conception exists . A subject eligible inclusion study ANY follow criterion apply : 1 . Known DPD deficiency 2 . Any investigational drug , chronic corticosteroid radiation therapy within 28 day study entry . 3 . History brain metastasis spinal cord compression , unless irradiate least 28 day study entry stable without steroid treatment &gt; 28 day . 4 . Stroke , major surgery , major tissue injury within 30 day study entry . 5 . Myocardial infarction within 12 month uncontrolled congestive heart failure , angina , arrhythmia , ECG abnormalities . 6 . No concurrent plan use topical pharmaceutical hand foot AquaphorÂ® . 7 . No concurrent plan use cytotoxic drug ( capecitabine ) . 8 . No dermatologic condition may complicate evaluation study . 9 . Other uncontrolled serious chronic disease condition investigator 's opinion could render compliance followup protocol problematic . 10 . Breast feed lactate . 11 . Unable return regular require interval reassessment study drug administration . 12 . Legal incapacity limit legal capacity , unless authorization grant legal guardian . 13 . Allergy lanolin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>HFS</keyword>
	<keyword>patient breast colon cancer receive capecitabine</keyword>
</DOC>